Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer
Noam Pondé, Lieveke Ameye, Matteo Lambertini, Marianne Paesmans, Martine Piccart, Evandro de Azambuja
Topics & Concepts
MedicineEjection fractionInternal medicineTrastuzumab emtansineHazard ratioCardiotoxicityCardiologyDiscontinuationBreast cancerPertuzumabHeart failureClinical endpointMetastatic breast cancerConfidence intervalOncologyCancerClinical trialChemotherapyHER2/EGFR in Cancer ResearchChemotherapy-induced cardiotoxicity and mitigationAdvanced Breast Cancer Therapies